3,3-Dimethyl-N-(diphenylmethyl)-2(S)-aminobutanamide | 183896-07-3

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 3,3-Dimethyl-N-(diphenylmethyl)-2(S)-aminobutanamide
• 英文别名: L-tert-leucine-N-benzhydrylamide；(2S)-2-amino-N-benzhydryl-3,3-dimethylbutanamide
• CAS: 183896-07-3
• 化学式: C₁₉H₂₄N₂O
• 分子量: 296.412
• InChiKey: DCLPWHRKKOERBR-QGZVFWFLSA-N

物化性质

• 沸点：
  484.9±45.0 °C(Predicted)
• 密度：
  1.063±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.6
• 重原子数：
  22
• 可旋转键数：
  5
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.32
• 拓扑面积：
  55.1
• 氢给体数：
  2
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  3,3-Dimethyl-N-(diphenylmethyl)-2(S)-aminobutanamide 在 palladium on activated charcoal N-甲基吗啉 、 盐酸 、 N-羟基-7-氮杂苯并三氮唑 、 Pd(OAc)2[P(2-tolyl)3]2 、 氢气 、 1-(3-二甲基氨基丙基)-3-乙基碳二亚胺 、 三乙胺 作用下， 以 乙醇 、 二氯甲烷 、 N,N-二甲基甲酰胺 为溶剂， 100.0 ℃ 、300.0 kPa 条件下， 反应 18.0h， 生成
  参考文献：
  名称：

  Discovery of potent and selective succinyl hydroxamate inhibitors of matrix metalloprotease-3 (Stromelysin-1)

  摘要：

  Structure-activity relationships are described for a series of succinyl hydroxamic acids 4a-o as potent and selective inhibitors of matrix metalloprotease-3 (stromelysin-1). Optimisation of P1' and P3' groups gave compound 4j (MMP-3 IC50 = 5.9nM) which was >140-fold less potent against MMP-1 (IC50 = 51,000nM), MMP-2 (IC50=1790nM), MMP-9 (IC50 = 840 nM) and MMP-14 (IC50 = 1900 nM). (C) 2001 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0960-894x(00)00720-4
• 作为产物：
  描述：

  tert-butyl N-[(2S)-1-(benzhydrylamino)-3,3-dimethyl-1-oxobutan-2-yl]carbamate 在 三氟甲磺酸三甲基硅酯 、 三乙胺 作用下， 以 二氯甲烷 为溶剂， 反应 1.03h， 生成 3,3-Dimethyl-N-(diphenylmethyl)-2(S)-aminobutanamide
  参考文献：
  名称：

  Mechanism of Amido-Thiourea Catalyzed Enantioselective Imine Hydrocyanation: Transition State Stabilization via Multiple Non-Covalent Interactions

  摘要：

  An experimental and computational investigation of amido-thiourea promoted imine hydrocyanation has revealed a new and unexpected mechanism of catalysis. Rather than direct activation of the imine by the thiourea, as had been proposed previously in related systems, the data are consistent with a mechanism involving catalyst-promoted proton transfer from hydrogen isocyanide to imine to generate diastereomeric iminium/cyanide ion pairs that are bound to catalyst through multiple noncovalent interactions; these ion pairs collapse to form the enantiomeric alpha-aminonitrile products. This mechanistic proposal is supported by the observation of a statistically significant correlation between experimental and calculated enantioselectivities induced by eight different catalysts (P << 0.01). The computed models reveal a basis for enantioselectivity that involves multiple stabilizing and destabilizing interactions between substrate and catalyst, including thiourea-cyanide and amide-iminium interactions.

  DOI：

  10.1021/ja9058958

文献信息

• Novel N-substituted alpha aminoacid amides as calcium channel modulators
  申请人：LILLY INDUSTRIES LIMITED

  公开号：EP0805147A1

  公开（公告）日：1997-11-05

  The compounds of formula I and derivatives thereof have been found to be active in tests that show modulation of voltage-dependent calcium channels, and are thus indicated for use in the treatment of diseases in which such modulation is beneficial, in particular diseases of the central nervous system.

  公式I及其衍生物的化合物已被发现在显示调节电压依赖性钙通道的测试中具有活性，因此适用于治疗对此类调节有益的疾病，特别是中枢神经系统疾病。
• Derivatives of succinamide and their use as metalloproteinase inhibitors
  申请人：British Biotech Pharmaceuticals, Ltd.

  公开号：US05840939A1

  公开（公告）日：1998-11-24

  Compounds of formula (I), wherein X is a --CO.sub.2 H or --CONHOH group; ##STR1## R.sub.4 is a group --CHR.sup.x R.sup.y wherein R.sup.x and R.sup.y independently represent optionally substituted phenyl or monocyclic heteroaryl rings, which optionally may be linked covalently to each other by a bond or by a C.sub.1 -C.sub.4 alkylene or C.sub.2 -C.sub.4 alkenylene bridge; and R.sub.1, R.sub.2, R.sub.3 and R.sub.5 as defined in the specification are selective inhibitors of stromelysin-1 and matrilysin relative to human fibroblast collagenase and 72 KDa gelatinase.

  化合物的式子（I），其中X是--CO.sub.2 H或--CONHOH基团; ## STR1 ## R.sub.4是一个--CHR.sup.x R.sup.y基团，其中R.sup.x和R.sup.y分别表示可选取代的苯基或单环杂环环，它们可以选择性地通过键或C.sub.1-C.sub.4烷基或C.sub.2-C.sub.4烯基桥链共价连接在一起; 而R.sub.1，R.sub.2，R.sub.3和R.sub.5在说明书中的定义是选择性地抑制stromelysin-1和matrilysin相对于人类成纤维细胞胶原酶和72 KDa明胶酶。
• Nitro-based selective inhibitors against matrix metalloproteinase-7 over matrix metalloproteinase-1
  作者：Mei-Hua Li、Yan-Feng Zhang、Hong-Rui Tian、Ming-Hua Zheng、Ming-Yang Yang、Hu-Lin Fang、Yu-Zhong Xie、Jing-Yi Jin

  DOI：10.1039/c5ra22271k

  日期：——

  A series of nitro-based dipeptidic compounds were synthesized and evaluated as matrix metalloproteinase (MMP) inhibitors, with improved selectivity for the inhibition of MMP-7 over MMP-1.

  一系列基于硝基的二肽化合物被合成并评估为基质金属蛋白酶（MMP）抑制剂，其选择性抑制MMP-7优于MMP-1。
• Catalytic, Asymmetric Michael-Aldol Annulations via a Stereodivergent/Stereoconvergent Path Operating under Curtin–Hammett Control
  作者：Mitchell T. Giordano、Katelyn M. Kitzinger、Pedro de Jesús Cruz、Shubin Liu、Jeffrey S. Johnson

  DOI：10.1021/jacs.3c03373

  日期：2023.6.7

  contiguous stereocenters (diastereoselection up to >20:1, enantioselectivity up to >99:1) in a Michael/aldol domino reaction between trisubstituted electrophilic alkenes and γ-nitroketones. Mechanistic studies suggest a scenario in which stereoconvergency is achieved by kinetically controlled cyclization after the initial diastereodivergent Michael addition. Diastereoconvergency during cyclization is shown

  双功能亚氨基正膦 (BIMP) 催化合成密集功能化环己醇的方法在三取代亲电子烯烃和 γ 之间的 Michael/aldol 多米诺骨牌反应中建立了五个连续的立体中心（非对映选择性高达 >20:1，对映选择性高达 >99:1） -硝基酮。机理研究表明，在初始非对映发散迈克尔加成后，通过动力学控制环化实现立体会聚。环化过程中的非对映会聚被证明是由科廷-哈米特动力学产生的，这一发现与之前在类似系统中报道的结晶驱动的立体会聚形成鲜明对比。尽管立体控制机制发生了变化，但操作属性仍然有吸引力，通常在过滤反应混合物时以分析纯形式分离出结晶产物。
• N-substituted alpha aminoacid amides as calcium channel modulators
  申请人：ELI LILLY AND COMPANY LIMITED

  公开号：EP1041064A2

  公开（公告）日：2000-10-04

  A pharmaceutical compound having the formula in which R1 is alkyl, -SO2R14 where R14 is alkyl, optionally substituted aryl or optionally substituted heteroaryl, R2 is hydrogen, alkyl optionally substituted with one or more hydroxy or C1-4 alkoxy groups, optionally substituted aryl, optionally substituted heteroaryl, -OR15, -P(O)(OR15)(OR16) or -NR15R16 where R15 and R16 are each hydrogen or alkyl, or -SO2R17 where R17 is hydrogen, alkyl, optionally substituted aryl or optionally substituted heteroaryl, R3 is hydrogen, -CN, -CO2R18, -CONR18R19,-CH18≡CHR19, -C≡CR18, -OCH2CO.R18, -SO2R18, -CH2OR18, -CH2OCO.R18, -CH2NHCOR18, -CH2N(COR18)2, -CHO, -OR18, -CH2NR18R19, -CH2OR18, -CH=NR18 or -CH=N-OR18, where R18 and R19 are each hydrogen or alkyl, X is a bond or -SO2-, R4, R5, R6, R8, R9 and R10 are each hydrogen or alkyl, n is 1 to 4, A is -CH2- or -YCO- where Y is a bond, -O-, optionally substituted phenylene, -CH=CH-, or -NR20- where R20 is hydrogen or alkyl, R7 is the C-α substituent of an amino acid or an ester thereof, or R6 and R7 together form a C3-5 alkylene chain optionally substituted by C1-4 alkyl or hydroxyl, or a group of the formula -CH2-Z-CH2- where Z is -CO-, -S-, -SO- or -SO2-, or R7 and R8 together form a C3 to C5 alkylene chain optionally substituted by C1-4 alkyl or hydroxyl, B is -CON(R21)-, -CON(R21)N(R22)- or where -x=y- is -C(R22)=N-, -N=C(R22)- or -N=N-, where R21 is hydrogen, alkyl or -NR23R24 where R23 and R24 are each hydrogen or alkyl, and where R22 is hydrogen or alkyl, or R8 and R21 together form a C2-4 alkylene chain, m is 0 to 2, R11 is hydrogen or alkyl, R12 is hydrogen, alkyl, optionally substituted aryl, optionally substituted heteroaryl, -CN, -OH, -CO2R25, -CONR25R26, where R25 and R26 are each hydrogen or alkyl, and R13 is alkyl, optionally substituted aryl or optionally substituted heteroaryl, or R12 and R13 together form a C3-8 cycloalkyl group or C3-8 cycloalkyl fused to optionally substituted phenyl; or a salt or ester thereof.

  一种药物化合物，其化学式为 其中 R1是烷基、-SO2R14，其中R14是烷基、任选取代的芳基或任选取代的杂芳基、 R2 是氢、任选被一个或多个羟基或 C1-4 烷氧基取代的烷基、任选被取代的芳基、任选被取代的杂芳基、-OR15、 -P(O)(OR15)(OR16)或-NR15R16（其中 R15 和 R16 各为氢或烷基），或-SO2R17（其中 R17 为氢、烷基、任选取代的芳基或任选取代的杂芳基）、 R3 是氢、-CN、-CO2R18、-CONR18R19、-CH18≡CHR19、-C≡CR18、-OCH2CO.R18、-SO2R18、-CH2OR18、-CH2OCO.R18、-CH2NHCOR18、-CH2N(COR18)2、-CHO、-OR18、-CH2NR18R19、-CH2OR18、-CH=NR18 或 -CH=N-OR18，其中 R18 和 R19 各为氢或烷基、 X 是键或-SO2-、 R4、R5、R6、R8、R9 和 R10 各为氢或烷基、 n 为 1 至 4、 A 是-CH2-或-YCO-，其中 Y 是键、-O-、任选取代的亚苯基、-CH=CH-或-NR20-，其中 R20 是氢或烷基、 R7 是氨基酸或其酯的 C-α 取代基，或 R6 和 R7 共同形成任选被 C1-4 烷基或羟基取代的 C3-5 亚烷基链，或式 -CH2-Z-CH2- 的基团，其中 Z 是 -CO-、-S-、-SO- 或 -SO2-、 或 R7 和 R8 共同形成任选被 C1-4 烷基或羟基取代的 C3 至 C5 亚烷基链、 B 是-CON(R21)-、-CON(R21)N(R22)-或 其中-x=y-是-C(R22)=N-、 -N=C(R22)-或-N=N-，其中 R21 是氢、烷基或-NR23R24，其中 R23 和 R24 分别是氢或烷基，R22 是氢或烷基，或 R8 和 R21 共同形成 C2-4 亚烷基链、 m 为 0 至 2、 R11 是氢或烷基 R12 是氢、烷基、任选取代的芳基、任选取代的杂芳基、-CN、-OH、-CO2R25、-CONR25R26，其中 R25 和 R26 各自是氢或烷基，以及 R13 是烷基、任选取代的芳基或任选取代的杂芳基，或 R12 和 R13 共同形成 C3-8 环烷基或与任选取代的苯基融合的 C3-8 环烷基； 或其盐或酯。